New corticosteroid-eluting porous polyethylene implant for the management of lower eyelid retraction: A pilot study

Daniel C. Garibaldi, Michael R. Robinson, Susan S. Lee, Dong Jun J Park, Howard F. Fine, Luke Deitz, Sam D'Anna, Peng Yuan, Nicholas Ranson, Michael Grant, Nicholas T. Iliff, Shannath L Merbs

Research output: Contribution to journalArticle

Abstract

PURPOSE: Lower eyelid retraction after trauma presents a challenging management problem. We postulated that a porous polyethylene (pPE) eyelid spacer coated with a polyvinyl alcohol (PVA) and triamcinolone acetonide (TA) matrix could deliver corticosteroid locally over extended periods and modulate inflammation and scar formation. We designed a pPE corticosteroid-eluting implant and evaluated its characteristics in vitro and in vivo. METHODS: The release characteristics of pPE implants coated with a PVA/TA matrix of low, intermediate, and high doses of TA were studied in vitro. The implants were then placed in the posterior lamella of lower eyelids of Dutch Belted rabbits for 12 weeks. Clinical events were recorded and eyelids were examined for gross and histologic features, including capsular thickness and degree of vascularity, fibrovascular ingrowth, and inflammatory response. RESULTS: In vitro, implants coated with the intermediate and high doses of TA released the drug at a steady rate for at least 78 days. In rabbits, the PVA and PVA/TA coating prevented fibrovascular ingrowth, except where breaks in the PVA/TA coat were present. Implants with PVA/TA coating demonstrated less inflammation and capsule vascularity. An inverse correlation between TA dose and capsule thickness was noted. CONCLUSIONS: We describe a novel drug-release pPE eyelid implant. The corticosteroid-eluting implant demonstrated antiangiogenic and anti-inflammatory properties, which could prove beneficial in the treatment of lower eyelid retraction.

Original languageEnglish (US)
Pages (from-to)424-429
Number of pages6
JournalOphthalmic Plastic and Reconstructive Surgery
Volume22
Issue number6
DOIs
StatePublished - Nov 2006

Fingerprint

Triamcinolone Acetonide
Polyethylene
Eyelids
Polyvinyl Alcohol
Adrenal Cortex Hormones
Capsules
Rabbits
Inflammation
Cicatrix
Anti-Inflammatory Agents
Wounds and Injuries

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery

Cite this

New corticosteroid-eluting porous polyethylene implant for the management of lower eyelid retraction : A pilot study. / Garibaldi, Daniel C.; Robinson, Michael R.; Lee, Susan S.; Park, Dong Jun J; Fine, Howard F.; Deitz, Luke; D'Anna, Sam; Yuan, Peng; Ranson, Nicholas; Grant, Michael; Iliff, Nicholas T.; Merbs, Shannath L.

In: Ophthalmic Plastic and Reconstructive Surgery, Vol. 22, No. 6, 11.2006, p. 424-429.

Research output: Contribution to journalArticle

Garibaldi, Daniel C. ; Robinson, Michael R. ; Lee, Susan S. ; Park, Dong Jun J ; Fine, Howard F. ; Deitz, Luke ; D'Anna, Sam ; Yuan, Peng ; Ranson, Nicholas ; Grant, Michael ; Iliff, Nicholas T. ; Merbs, Shannath L. / New corticosteroid-eluting porous polyethylene implant for the management of lower eyelid retraction : A pilot study. In: Ophthalmic Plastic and Reconstructive Surgery. 2006 ; Vol. 22, No. 6. pp. 424-429.
@article{6c56e769a8bd4e1ebd511c16534f0350,
title = "New corticosteroid-eluting porous polyethylene implant for the management of lower eyelid retraction: A pilot study",
abstract = "PURPOSE: Lower eyelid retraction after trauma presents a challenging management problem. We postulated that a porous polyethylene (pPE) eyelid spacer coated with a polyvinyl alcohol (PVA) and triamcinolone acetonide (TA) matrix could deliver corticosteroid locally over extended periods and modulate inflammation and scar formation. We designed a pPE corticosteroid-eluting implant and evaluated its characteristics in vitro and in vivo. METHODS: The release characteristics of pPE implants coated with a PVA/TA matrix of low, intermediate, and high doses of TA were studied in vitro. The implants were then placed in the posterior lamella of lower eyelids of Dutch Belted rabbits for 12 weeks. Clinical events were recorded and eyelids were examined for gross and histologic features, including capsular thickness and degree of vascularity, fibrovascular ingrowth, and inflammatory response. RESULTS: In vitro, implants coated with the intermediate and high doses of TA released the drug at a steady rate for at least 78 days. In rabbits, the PVA and PVA/TA coating prevented fibrovascular ingrowth, except where breaks in the PVA/TA coat were present. Implants with PVA/TA coating demonstrated less inflammation and capsule vascularity. An inverse correlation between TA dose and capsule thickness was noted. CONCLUSIONS: We describe a novel drug-release pPE eyelid implant. The corticosteroid-eluting implant demonstrated antiangiogenic and anti-inflammatory properties, which could prove beneficial in the treatment of lower eyelid retraction.",
author = "Garibaldi, {Daniel C.} and Robinson, {Michael R.} and Lee, {Susan S.} and Park, {Dong Jun J} and Fine, {Howard F.} and Luke Deitz and Sam D'Anna and Peng Yuan and Nicholas Ranson and Michael Grant and Iliff, {Nicholas T.} and Merbs, {Shannath L}",
year = "2006",
month = "11",
doi = "10.1097/01.iop.0000245487.61479.56",
language = "English (US)",
volume = "22",
pages = "424--429",
journal = "Ophthalmic Plastic and Reconstructive Surgery",
issn = "0740-9303",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - New corticosteroid-eluting porous polyethylene implant for the management of lower eyelid retraction

T2 - A pilot study

AU - Garibaldi, Daniel C.

AU - Robinson, Michael R.

AU - Lee, Susan S.

AU - Park, Dong Jun J

AU - Fine, Howard F.

AU - Deitz, Luke

AU - D'Anna, Sam

AU - Yuan, Peng

AU - Ranson, Nicholas

AU - Grant, Michael

AU - Iliff, Nicholas T.

AU - Merbs, Shannath L

PY - 2006/11

Y1 - 2006/11

N2 - PURPOSE: Lower eyelid retraction after trauma presents a challenging management problem. We postulated that a porous polyethylene (pPE) eyelid spacer coated with a polyvinyl alcohol (PVA) and triamcinolone acetonide (TA) matrix could deliver corticosteroid locally over extended periods and modulate inflammation and scar formation. We designed a pPE corticosteroid-eluting implant and evaluated its characteristics in vitro and in vivo. METHODS: The release characteristics of pPE implants coated with a PVA/TA matrix of low, intermediate, and high doses of TA were studied in vitro. The implants were then placed in the posterior lamella of lower eyelids of Dutch Belted rabbits for 12 weeks. Clinical events were recorded and eyelids were examined for gross and histologic features, including capsular thickness and degree of vascularity, fibrovascular ingrowth, and inflammatory response. RESULTS: In vitro, implants coated with the intermediate and high doses of TA released the drug at a steady rate for at least 78 days. In rabbits, the PVA and PVA/TA coating prevented fibrovascular ingrowth, except where breaks in the PVA/TA coat were present. Implants with PVA/TA coating demonstrated less inflammation and capsule vascularity. An inverse correlation between TA dose and capsule thickness was noted. CONCLUSIONS: We describe a novel drug-release pPE eyelid implant. The corticosteroid-eluting implant demonstrated antiangiogenic and anti-inflammatory properties, which could prove beneficial in the treatment of lower eyelid retraction.

AB - PURPOSE: Lower eyelid retraction after trauma presents a challenging management problem. We postulated that a porous polyethylene (pPE) eyelid spacer coated with a polyvinyl alcohol (PVA) and triamcinolone acetonide (TA) matrix could deliver corticosteroid locally over extended periods and modulate inflammation and scar formation. We designed a pPE corticosteroid-eluting implant and evaluated its characteristics in vitro and in vivo. METHODS: The release characteristics of pPE implants coated with a PVA/TA matrix of low, intermediate, and high doses of TA were studied in vitro. The implants were then placed in the posterior lamella of lower eyelids of Dutch Belted rabbits for 12 weeks. Clinical events were recorded and eyelids were examined for gross and histologic features, including capsular thickness and degree of vascularity, fibrovascular ingrowth, and inflammatory response. RESULTS: In vitro, implants coated with the intermediate and high doses of TA released the drug at a steady rate for at least 78 days. In rabbits, the PVA and PVA/TA coating prevented fibrovascular ingrowth, except where breaks in the PVA/TA coat were present. Implants with PVA/TA coating demonstrated less inflammation and capsule vascularity. An inverse correlation between TA dose and capsule thickness was noted. CONCLUSIONS: We describe a novel drug-release pPE eyelid implant. The corticosteroid-eluting implant demonstrated antiangiogenic and anti-inflammatory properties, which could prove beneficial in the treatment of lower eyelid retraction.

UR - http://www.scopus.com/inward/record.url?scp=33751203541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751203541&partnerID=8YFLogxK

U2 - 10.1097/01.iop.0000245487.61479.56

DO - 10.1097/01.iop.0000245487.61479.56

M3 - Article

C2 - 17117094

AN - SCOPUS:33751203541

VL - 22

SP - 424

EP - 429

JO - Ophthalmic Plastic and Reconstructive Surgery

JF - Ophthalmic Plastic and Reconstructive Surgery

SN - 0740-9303

IS - 6

ER -